Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HX009 in relapsed or refractory lymphoma in China
CTR20213391Phase 2Completed
- Sponsor
- Hansi Bio
- Start
- Dec 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of HX009 in lymphoma, diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma (PTCL), classical Hodgkin lymphoma (cHL), mantle cell lymphoma (MCL), sponsored by Hansi Bio. Started Dec 2021; status: completed.
02
Drugs
HX009
03
Conditions
lymphomadiffuse large B-cell lymphoma (DLBCL)peripheral T-cell lymphoma (PTCL)classical Hodgkin lymphoma (cHL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20213391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213391.